Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry

被引:71
作者
Baker, SD [1 ]
Zhao, M
He, P
Carducci, MA
Verweij, J
Sparreboom, A
机构
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
[2] Dr Daniel Den Hoed Canc Ctr, Erasmus Med Ctr, NL-3008 AE Rotterdam, Netherlands
[3] NCI, Bethesda, MD 20892 USA
关键词
docetaxel; polysorbate 80 (Tween 80); LC/MS/MS; pharmacokinetics;
D O I
10.1016/j.ab.2003.09.038
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An analytical procedure for the simultaneous determination of the anticancer agent docetaxel (Taxotere) and its formulation vehicle polysorbate 80 (Tween 80) in human plasma samples is described. Sample pretreatment involved a double liquid-liquid extraction step with a mixture of acetonitrile/n-butyl chloride (1/4, v/v). Separation of the compounds of interest, including the internal standard paclitaxel, was achieved on a reversed-phase Waters X-Terra mass spectrometry (MS) column (50 x 2.1 mm internal diameter) packed with a 3.5-mum octadecyl stationary phase, using isocratic elution. Detection of docetaxel and polysorbate 80 was performed using tandem MS detection with electrospray ionization. Validation results indicated that the method is accurate and precise and has lower limits of quantitation of 0.500 nM (similar to0.4 ng/ml) and 1.00 mug/ml for docetaxel and polysorbate 80, respectively. The method was subsequently used to measure concentrations of docetaxel and polysorbate 80 in plasma samples in support of a project to assess the influence of polysorbate 80 concentrations on the disposition and toxicity profile of docetaxel in cancer patients receiving Taxotere. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:276 / 284
页数:9
相关论文
共 25 条
[1]  
Ardiet CJ, 1999, INVEST NEW DRUG, V17, P325
[2]  
Bardelmeijer HA, 2002, CANCER RES, V62, P6158
[3]   Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel [J].
Bruno, R ;
Vivier, N ;
Veyrat-Follet, C ;
Montay, G ;
Rhodes, GR .
INVESTIGATIONAL NEW DRUGS, 2001, 19 (02) :163-169
[4]   Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction [J].
Ciccolini, J ;
Catalin, J ;
Blachon, MF ;
Durand, A .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2001, 759 (02) :299-306
[5]  
CRISPENS CG, 1988, ANTICANCER RES, V8, P1341
[6]   Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine [J].
Garg, MB ;
Ackland, SP .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2000, 748 (02) :383-388
[7]   Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies [J].
Goh, BC ;
Lee, SC ;
Wang, LZ ;
Fan, L ;
Guo, JY ;
Lamba, J ;
Schuetz, E ;
Lim, R ;
Lim, HL ;
Ong, AB ;
Lee, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3683-3690
[8]  
GUSTAFSON DL, 2003, CANC CHEMOTHER PHARM
[9]   Validation of bioanalytical chromatographic methods [J].
Hartmann, C ;
Smeyers-Verbeke, J ;
Massart, DL ;
McDowall, RD .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (02) :193-218
[10]   Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins [J].
Loos, WJ ;
Baker, SD ;
Verweij, J ;
Boonstra, JG ;
Sparreboom, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (04) :364-371